z-logo
Premium
Immunohistochemical study of endometrial high‐grade endometrioid carcinoma with or without a concurrent low‐grade component: implications for pathogenetic and survival differences
Author(s) -
Mao TsuiLien,
Ayhan Ayse,
Kuo KuangTing,
Lin MingChieh,
Tseng LiHui,
Ogawa Hiroshi
Publication year - 2015
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12664
Subject(s) - pten , microsatellite instability , immunohistochemistry , carcinoma , cancer research , pathogenesis , phenotype , pathology , biology , medicine , signal transduction , microsatellite , pi3k/akt/mtor pathway , gene , biochemistry , allele
Aims To compare the clinical and pathogenetic differences between high‐grade ( HG ) endometrioid carcinomas with and without concurrent low‐grade ( LG ) components. Methods and results The expression of ARID 1A, PTEN , p53 and mismatch repair ( MMR ) proteins in HG endometrioid carcinomas without ( n  = 19) or with ( n  = 22) concurrent LG endometrioid carcinomas was studied by immunohistochemistry. Microsatellite instability ( MSI ) was also tested in 31 cases. The frequencies of ARID 1A loss, PTEN loss, MMR deficiency or MSI and aberrant p53 expression were 58%, 37%, 37% and 47% in pure HG tumours, and 77%, 45%, 55% and 32% in HG tumours with concurrent LG components ( P  = 0.07 for ARID 1A; P  > 0.1 for other proteins). Pure HG tumours had a higher frequency of the type II phenotype (positive for ARID 1A, PTEN and MMR proteins; aberrant p53 expression) than HG tumours with concurrent LG components (21% versus 5%) ( P  = 0.2). The 5‐year overall survival rate was worse for pure HG tumours (61.7%) than for HG tumours with concurrent LG components (93.3%) ( P  = 0.07). Conclusions HG endometrioid carcinomas are heterogeneous in pathogenesis: some arise from LG endometrioid carcinomas via the type I pathway, whereas others may arise de novo through either the type I pathway or the type II pathway, and have a different prognosis. Thus, HG endometrioid carcinomas should be subclassified properly and treated accordingly.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here